<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536611</url>
  </required_header>
  <id_info>
    <org_study_id>SYNH-K201813</org_study_id>
    <nct_id>NCT03536611</nct_id>
  </id_info>
  <brief_title>Dabigatran Versus Warfarin With NVAF Who Undergo PCI</brief_title>
  <acronym>COACH-AF-PCI</acronym>
  <official_title>A Randomized Study Comparing Dabigatran Etexilate Versus Warfarin in Chinese Patients With Nonvalvular Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention With Stenting (DES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to compare the efficacy and safety of dabigatran ethidium b.i.d.+ clopidogrel +&#xD;
      ASA [100 mg q.d. *1 month] and warfarin + clopidogrel + ASA [100 mg, q.d.*1 month] in Chinese&#xD;
      NVAF patients undergoing PCI with stenting (elective or due to ACS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, randomized, controlled, prospective study.The object of&#xD;
      this study is to compare the safety and efficacy of dabigatran etexilate combined with dual&#xD;
      anti-platelet therapy versus warfarin combined with dual anti-platelet therapy in Chinese&#xD;
      patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention.&#xD;
&#xD;
      The subjects are randomized into study group and control group using central randomization&#xD;
      for open-label dosing:(1) Study group: dabigatran etexilate 110 mg bid + aspirin 100 mg qd +&#xD;
      clopidogrel 75 mg qd. Aspirin is withdrawn 1 month later;(2) Control group: warfarin&#xD;
      (according to clinical routine monitoring of INR, maintain the therapeutic rang at 2.0-3.0) +&#xD;
      aspirin 100 mg qd + clopidogrel 75 mg qd. Aspirin is withdrawn 1 month later;All patients&#xD;
      should receive the study medication for 6 month.&#xD;
&#xD;
      Primary endpoint:Time to the first occurrence of BARC-defined (grade 2-5) clinically relevant&#xD;
      bleeding.&#xD;
&#xD;
      Key secondary endpoint:Time to the first occurrence of net clinical adverse events. Net&#xD;
      clinical adverse event is composed of major cardiovascular and cerebrovascular adverse events&#xD;
      (all death, recurrent myocardial infarction, ischemia-induced revascularization of the target&#xD;
      vessel, or stroke/systemic embolism) or BARC-defined (grade 2-5) clinically relevant&#xD;
      bleeding.&#xD;
&#xD;
      Secondary endpoints:1) Major cardiovascular and cerebrovascular adverse events 2) Major&#xD;
      bleeding or clinically relevant non-major bleeding (ISTH definition) 3) Major bleeding (ISTH&#xD;
      definition) 4) Any bleeding event (BARC-defined grade 1-5) 5) Clinically relevant bleeding&#xD;
      (BARC-defined grade 2-5) 6) Bleeding (BARC-defined grade 3-5)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinically relevant bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Time to the first occurrence of BARC-defined (grade 2-5) clinically relevant bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the first occurrence of major cardiovascular and cerebrovascular adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Time to the first occurrence of net clinical adverse events. Net clinical adverse event is composed of major cardiovascular and cerebrovascular adverse events (all death, recurrent myocardial infarction, ischemia-induced revascularization of the target vessel, or stroke/systemic embolism) or BARC-defined (grade 2-5) clinically relevant bleeding.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>other events</measure>
    <time_frame>24 months</time_frame>
    <description>Major cardiovascular and cerebrovascular adverse events&#xD;
Major bleeding or clinically relevant non-major bleeding (ISTH definition)&#xD;
Major bleeding (ISTH definition)&#xD;
Any bleeding event (BARC-defined grade 1-5)&#xD;
Clinically relevant bleeding (BARC-defined grade 2-5)&#xD;
Bleeding (BARC-defined grade 3-5)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1120</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran</intervention_name>
    <description>dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months</description>
    <arm_group_label>dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months</description>
    <arm_group_label>warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥18 years;&#xD;
&#xD;
          2. Patients with non-secondary (e.g., pericarditis, hyperthyroidism, recent surgery,&#xD;
             etc.) nonvalvular atrial fibrillation requiring long-term anticoagulant treatment;&#xD;
&#xD;
          3. Patients who have PCI indications and coronary heart disease that was successfully&#xD;
             treated with drug-eluting stenting (DES);&#xD;
&#xD;
          4. Patients who sign the informed consent form. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with mechanical or biological heart valve prosthesis;&#xD;
&#xD;
          2. Patients proposed to undergo left atrial appendage occlusion or atrial fibrillation&#xD;
             radiofrequency ablation&#xD;
&#xD;
          3. Cardiogenic shock during current hospitalization;&#xD;
&#xD;
          4. Patients who have used fibrinolytic agents within 24 hours of randomization that, in&#xD;
             the opinion of the Investigator, will put the patient at high risk of bleeding;&#xD;
&#xD;
          5. Stroke within 1 month prior to screening visit;&#xD;
&#xD;
          6. Patients, who in the opinion of the Investigator, have had major surgery within the&#xD;
             month prior to screening;&#xD;
&#xD;
          7. Patient has received an organ transplant or is on a waiting list for an organ&#xD;
             transplant;&#xD;
&#xD;
          8. History of intraocular, spinal, retroperitoneal or a traumatic intra-articular&#xD;
             bleeding unless the causative factor has been permanently eliminated or repaired (e.g.&#xD;
             by surgery);&#xD;
&#xD;
          9. Gastrointestinal (GI) haemorrhage within one month prior to screening, unless, in the&#xD;
             opinion of the Investigator, the cause has been permanently eliminated (e.g. by&#xD;
             surgery);&#xD;
&#xD;
         10. Major bleeding episode (reduction in the haemoglobin level of at least 2 g/dL,&#xD;
             transfusion of at least two units of blood, or symptomatic bleeding in a critical area&#xD;
             or organ) including life-threatening bleeding episode (symptomatic intracranial&#xD;
             bleeding, bleeding with a decrease in the haemoglobin level of at least 5 g/dL or&#xD;
             bleeding requiring transfusion of at least 4 units of blood or inotropic agents or&#xD;
             necessitating surgery) in one month prior to screening visit;&#xD;
&#xD;
         11. Haemorrhagic disorder or bleeding diathesis (e.g. von Willebrand disease, haemophilia&#xD;
             A or B or other hereditary bleeding disorder, history of spontaneous intra-articular&#xD;
             bleeding, history of prolonged bleeding after surgery/intervention);&#xD;
&#xD;
         12. Anaemia (haemoglobin &lt;10 g/dL) or thrombocytopenia including heparin-induced&#xD;
             thrombocytopenia (platelet count &lt;100×109/L) at screening (Visit 1);&#xD;
&#xD;
         13. Severe renal impairment (estimated CrCl calculated by Cockcroft-Gault equation) &lt;30&#xD;
             mL/min at screening;&#xD;
&#xD;
         14. Active liver disease as indicated by at least one of the following:&#xD;
&#xD;
               -  Prior and persistent alanine aminotransferase (ALT) or Aspartate transaminase&#xD;
                  (AST) or alkaline phosphatase (AP) &gt;3 upper limit of normal (ULN);&#xD;
&#xD;
                    -  Known active hepatitis C; ③Known active hepatitis B; ④Known active hepatitis&#xD;
                       A;&#xD;
&#xD;
         15. Recent malignancy or radiation therapy (≤6 months) unless, in the opinion of the&#xD;
             Investigator, the estimated life expectancy is greater than 36 months;&#xD;
&#xD;
         16. Need for continued treatment with systemic ketoconazole, itraconazole, posaconazole,&#xD;
             cyclosporine, tacrolimus, dronedarone, rifampicin, phenytoin, carbamazepine, or any&#xD;
             cytotoxic/myelosuppressive therapy;&#xD;
&#xD;
         17. Patients who, in the Investigator's opinion, need continuous treatment with&#xD;
             Non-Steroidal Anti-Inflammatory Drugs (NSAIDs);&#xD;
&#xD;
         18. Patients with a known allergy to dabigatran etexilate or to the excipients used for&#xD;
             the capsule of the drug&#xD;
&#xD;
         19. Patients with a known allergy to warfarin tablets or to the excipients&#xD;
&#xD;
         20. Patients who, in the Investigator's opinion, should not be treated with OAC;&#xD;
&#xD;
         21. Patients with a contraindication to clopidogrel, or ASA&#xD;
&#xD;
         22. Pre-menopausal women (last menstruation ≤1 year prior to screening) who experienced&#xD;
             any of the following conditions:&#xD;
&#xD;
               -  Are pregnant or breast feeding; ②Are pregnant surgically sterile; ③Are of child&#xD;
                  bearing potential and not practising two acceptable methods of birth control, or&#xD;
                  do not plan to continue practising an acceptable method of birth control&#xD;
                  throughout the trial. (Acceptable methods of birth control are oral or parenteral&#xD;
                  (patch, injection, implant) hormonal contraception which has been used&#xD;
                  continuously for at least one month prior to the first dose of study medication,&#xD;
                  intrauterine device or intrauterine system, double-barrier method of&#xD;
                  contraception (condom and occlusive cap or condom and spermicidal agent), male&#xD;
                  sterilization and complete sexual abstinence (if acceptable by local&#xD;
                  authorities)). Periodic abstinence is not an acceptable method of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zulu Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The General Hospital of Northern Theater Command</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Liang, PhD</last_name>
    <phone>17790991573</phone>
    <email>lming000919@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Liang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>January 3, 2019</last_update_submitted>
  <last_update_submitted_qc>January 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Han Yaling</investigator_full_name>
    <investigator_title>Director, clinical professor</investigator_title>
  </responsible_party>
  <keyword>dabigatran</keyword>
  <keyword>warfarin</keyword>
  <keyword>non-valve atrial fibrillation</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

